Ang, JE; Pandher, R; Ang, JC; Asad, YJ; Henley, A; Valenti, M; Box, G; ... Raynaud, FI; + view all Ang, JE; Pandher, R; Ang, JC; Asad, YJ; Henley, A; Valenti, M; Box, G; De Haven Brandon, A; Baird, RR; Friedman, L; Derynck, M; Vanhaesebroeck, B; Eccles, SA; Kaye, SB; Workman, P; De Bono, JS; Raynaud, FI; - view fewer (2016) Plasma metabolomic changes following PI3K inhibition as pharmacodynamic biomarkers: preclinical discovery to Phase I trial evaluation. Molecular Cancer Therapeutics , 15 (6) pp. 1412-1424. 10.1158/1535-7163.MCT-15-0815.

Preview

Text Vanhaesebroeck_Mol Cancer Ther-2016-Ang-1535-7163.MCT-15-0815.pdf Download (1MB) | Preview

Abstract

Phosphoinositide-3-kinase (PI3K) plays a key role in cellular metabolism and cancer. Using a mass spectrometry-based metabolomics platform, we discovered that plasma concentrations of 26 metabolites, including amino acids, acylcarnitines and phosphatidylcholines, were decreased in mice bearing PTEN-deficient tumors compared with non-tumor bearing controls and in addition were increased following dosing with Class I PI3K inhibitor pictilisib (GDC-0941). These candidate metabolomics biomarkers were evaluated in a Phase I dose-escalation clinical trial of pictilisib. Time- and dose-dependent effects were observed in patients for 22 plasma metabolites. The changes exceeded baseline variability, resolved after drug washout and were recapitulated on continuous dosing. Our study provides a link between modulation of the PI3K pathway and changes in the plasma metabolome and demonstrates that plasma metabolomics is a feasible and promising strategy for biomarker evaluation. Also, our findings provide additional support for an association between insulin resistance, branched-chain amino acids and related metabolites following PI3K inhibition.

Download activity - last month

Export as CSVJSONXML

Download activity - last 12 months

Export as CSVXMLJSON

Downloads by country - last 12 months

Export as CSVJSONXML

Archive Staff Only

View Item